Introduction -- Oncogene Addiction in Solid Tumors -- Pharmacology and Clinical Development of New Molecularly Targeted Agents -- Biomarkers as Prognostic, Predictive and Surrogate Endpoints -- Evaluation of Response in Malignant Tumors Treated with Targeted Agents -- Targeted Therapies for HER2-Positive Breast Cancer -- Role of PARP Inhibitors in Triple Negative Breast Cancer (TNBC) -- Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck -- Targeted Therapies for NSCLC -- Targeted Therapies for Gastric Cancer -- Targeted Therapies for Pancreatic Cancer -- Targeted Therapies in Hepatocellular Carcinoma -- Targeted Therapies for Colorectal Cancer -- Targeted Therapy in Gastrointestinal Stromal Tumors -- Targeted Therapies in Kidney Cancer -- Targeted Therapies in Melanoma -- Targeted Therapies for Prostate Cancer -- Targeted Therapies for Bone Metastases.

This volume provides readers a comprehensive and state-of-the-art overview about the range of applications of targeted therapies for solid tumors. The sections of the book have been structured to review the oncogene addicted tumors, the pharmacology and clinical development of new molecularly targeted agents, the use of biomarkers as prognostic, predictive and surrogate endpoints, and the evaluation of tumor response and specific malignancies treated with targeted agents. The book also covers some of the newest developments in cancer therapy that are not adequately covered by any current available literature. Written by recognized experts in the field, Targeted Therapies for Solid Tumors: A Handbook for Moving Toward New Frontiers in Cancer TreatmentÂ{u0CAF}vides a unique and valuable resource in the field of molecular oncology, both for those currently in training, and for those already in clinical or research practice.